Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Inhaled GSK3923868 in COPD
NCT05677347Phase 1Completed
- Sponsor
- GSK
- Start
- Jan 2023
- Primary completion
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of GSK3923868 in chronic obstructive pulmonary disease (COPD) (4 arms), sponsored by GSK. Primary endpoints: Number of Participants With Non-serious Adverse Events (Non-SAEs) and Serious Adverse Events (SAEs) Following Single Dose of GSK3923868 up to 18 days, Number of Participants With Non-serious Adverse Events (Non-SAEs) and Serious Adverse Events (SAEs) Following Repeat Dose of GSK3923868 up to 29 days and 7 more. Started Jan 2023; status: completed.
02
Drugs
GSK3923868
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT05677347.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05677347.